NCT05725057 - Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

September 4, 2024

Study Completion Date

October 4, 2024

Conditions

PsoriasisPlaque Psoriasis

Interventions

DRUG

AX-158

Subjects randomized to this arm will receive AX-158 treatment for 28 days with a 30 day safety follow-up period.

DRUG

Placebo

Subjects randomized to this arm will receive placebo treatment for 28 days with a 30 day safety follow-up period.

Trial Locations (6)

Accellacare Northamptonshire, Corby

Accellacare Warwickshire, Coventry

MEU, Manchester

Accellacare North London, Northwood

Accellacare South London, Orpington

Accellacare Yorkshire, Shipley